Skip to main
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Indus is viewed positively by financial analysts due to its strong commercial execution and investments in growth, with key drugs AUSTEDO and UZEDY showing promising results and potential for market expansion. However, there are concerns about competition and potential side effects for their new drugs. The company is focused on branded therapies and has a diverse portfolio, including generics and biosimilars. Teva's net-debt/EBITDA ratio is expected to improve in the future, and their updated price target is $42.

Bears say

Teva Pharmaceutical Indus is facing significant challenges due to its heavy reliance on the generic drug market, which is highly competitive and faces pricing pressures. Additionally, the company's recent pivot towards branded drugs may not have the desired impact on growth, and could potentially strain its balance sheet. Although upcoming launches and M&A activity may provide short-term growth, long-term success may be difficult to sustain without a strong pipeline and a clear strategy for its generic business.

Teva Pharmaceutical (TEVA) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Buy based on their latest research and market trends.

According to 10 analysts, Teva Pharmaceutical (TEVA) has a Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.